Royalty Pharma (RPRX) FCF Payout Ratio (QoQ) (2019 - 2026)
Royalty Pharma (RPRX) FCF Payout Ratio (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.60% |
| Dec 31, 2025 | 429.78% |
| Sep 30, 2025 | -224.29% |
| Jun 30, 2025 | 17.59% |
| Mar 31, 2025 | -29.20% |
| Dec 31, 2024 | 302.25% |
| Sep 30, 2024 | 85.50% |
| Jun 30, 2024 | -887.48% |
| Mar 31, 2024 | 151.88% |
| Dec 31, 2023 | -141.94% |
| Sep 30, 2023 | 355.93% |
| Jun 30, 2023 | -27.83% |
| Mar 31, 2023 | -25.48% |
| Dec 31, 2022 | 308.75% |
| Sep 30, 2022 | -152.52% |
| Jun 30, 2022 | 26.11% |
| Mar 31, 2022 | 110.37% |
| Dec 31, 2021 | -399.59% |
| Sep 30, 2021 | -145.19% |
| Jun 30, 2021 | -94.13% |